ונקו-טבע 500 מג Ísrael - hebreska - Ministry of Health

ונקו-טבע 500 מג

teva pharmaceutical industries ltd, israel - vancomycin as hydrochloride - אבקה מיובשת בהקפאה להזרקה - vancomycin as hydrochloride 500 mg/vial - vancomycin - vancomycin - vancomycin hydrochloride is indicated for the treatment of severe or serious infections due to susceptible strains of methicillin - resistant (beta-iactam-resistant) staphylococci. it is also indicated for administration to penicillin-allergic patients as well patients who have failed to respond to or who cannot receive other drugs including cephalosporins or penicillins and for infections due to vancomycin-susceptible organisms that are resistant to other antimicrobial drugs. vancomycin hydrochloride is indicated for first-line therapy when methicillin-resistant staphylococci are suspected but when susceptibility data become available appropriate therapy should be instituted. vancomycin hydrochloride is effective in the treatment of staphylococcal endocarditis as well as in other infections due to staphylococci including lower respiratory tract infections septicemia skin and skin - stucture infection and bone infections. antibiotic therapy is as an adjunct to appropriate surgical measures when staphylococcal

רג'יטין אמפולות 10 מ"ג/מ"ל Ísrael - hebreska - Ministry of Health

רג'יטין אמפולות 10 מ"ג/מ"ל

novartis pharma services ag - phentolamine mesylate 10 mg/ml - solution for injection - phentolamine - 1. management of hypertensive crises which may occur in patients with phaeochromocytoma e.g. during pre-operative preparation and surgical intervention. 2. diagnosis of phaeochromocytoma by the regitine test if other specific tests are not available.

אלבסקו 40 Ísrael - hebreska - Ministry of Health

אלבסקו 40

agis commercial agency (1989) - ciclesonide 40 mcg - solution for inhalation - ciclesonide - treatment to control persistent asthma in adults and adolescents ( 12 years and older) .

אלבסקו 80 Ísrael - hebreska - Ministry of Health

אלבסקו 80

agis commercial agency (1989) - ciclesonide 80 mcg - solution for inhalation - ciclesonide - treatment to control persistent asthma in adults and adolescents ( 12 years and older) .

אלבסקו 160 Ísrael - hebreska - Ministry of Health

אלבסקו 160

agis commercial agency (1989) - ciclesonide 160 mcg - solution for inhalation - ciclesonide - treatment to control persistent asthma in adults and adolescents ( 12 years and older) .

טאלץ 80 מג Ísrael - hebreska - Ministry of Health

טאלץ 80 מג

eli lilly israel ltd, israel - ixekizumab - תמיסה להזרקה - ixekizumab 80 mg / 1 ml - ixekizumab

קסמיאול Ísrael - hebreska - Ministry of Health

קסמיאול

dexcel ltd, israel - betamethasone as dipropionate; calcipotriol as hydrate - ג'ל - betamethasone as dipropionate 0.5 mg / 1 g; calcipotriol as hydrate 50 mcg / 1 g - betamethasone - betamethasone - topical treatment of psoriasis vulgaris on the scalp and topical treatment of mild to moderate “non-scalp” plaque psoriasis vulgaris in adults 18 years of age and older.

אקטיק 200 מקג Ísrael - hebreska - Ministry of Health

אקטיק 200 מקג

abic marketing ltd, israel - fentanyl as citrate - טבליות דחוסות על מקל - fentanyl as citrate 200 mcg/dose - fentanyl - fentanyl - actiq is indicated only for the management of breakthrough cancer pain in patients 16 and older with malignancies who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain.

אקטיק 600 מקג Ísrael - hebreska - Ministry of Health

אקטיק 600 מקג

abic marketing ltd, israel - fentanyl as citrate - טבליות דחוסות על מקל - fentanyl as citrate 600 mcg/dose - fentanyl - fentanyl - actiq is indicated only for the management of breakthrough cancer pain in patients 16 and older with malignancies who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain.

אקטיק 1200 מקג Ísrael - hebreska - Ministry of Health

אקטיק 1200 מקג

abic marketing ltd, israel - fentanyl as citrate - טבליות דחוסות על מקל - fentanyl as citrate 1200 mcg/dose - fentanyl - fentanyl - actiq is indicated only for the management of breakthrough cancer pain in patients 16 and older with malignancies who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain.